These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35877259)

  • 21. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma.
    Akce M; Chang E; Haeri M; Perez M; Finch CJ; Udden MM; Mims MP
    Case Rep Hematol; 2016; 2016():3598547. PubMed ID: 27957358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
    Nwanwene K; Khan NAJ; Alsharedi M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211017423. PubMed ID: 34032157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Arcuri and Americo "Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis".
    Davies FE; Saunders E; Bourhis F; Guyot P
    Ann Hematol; 2022 Jul; 101(7):1599-1601. PubMed ID: 35179641
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasmablastic lymphoma of the oral cavity with breast recurrence: a case report.
    Samoon Z; Idrees R; Masood N; Ansari TZ
    BMC Res Notes; 2015 May; 8():180. PubMed ID: 25933603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary plasmablastic lymphoma of the gastrointestinal tract: A series of 13 HIV-negative cases and a review of literature.
    Fu Z; Wang H; Lauwers GY; Jiang K; Jayaratne NL; Bridglal S; Dong N; Wang E; Chen L; Barclift DP; Zhang L
    Ann Diagn Pathol; 2023 Dec; 67():152204. PubMed ID: 37639839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.
    Elyamany G; Alzahrani AM; Aljuboury M; Mogadem N; Rehan N; Alsuhaibani O; Alabdulaaly A; Al-Mussaed E; Elhag I; AlFiaar A
    Diagn Pathol; 2015 Jun; 10():78. PubMed ID: 26108914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmablastic lymphoma: current knowledge and future directions.
    Li JW; Peng HL; Zhou XY; Wang JJ
    Front Immunol; 2024; 15():1354604. PubMed ID: 38415257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity.
    Mota F; Mesquita B; Carvalho S; Coelho A; Velho G; Lima M; Selores M
    Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
    Yan M; Dong Z; Zhao F; Chauncey T; Deauna-Limayo D; Wang-Rodriguez J; Liu D; Wang HY; Pilz R
    Eur J Haematol; 2014 Jul; 93(1):77-80. PubMed ID: 24528507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
    Dittus C; Grover N; Ellsworth S; Tan X; Park SI
    Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.
    Tchernonog E; Faurie P; Coppo P; Monjanel H; Bonnet A; Algarte Génin M; Mercier M; Dupuis J; Bijou F; Herbaux C; Delmer A; Fabiani B; Besson C; Le Gouill S; Gyan E; Laurent C; Ghesquieres H; Cartron G
    Ann Oncol; 2017 Apr; 28(4):843-848. PubMed ID: 28031174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, pathological and molecular features of plasmablastic lymphoma arising in the gastrointestinal tract: A review and reappraisal.
    Sanguedolce F; Zanelli M; Zizzo M; Martino G; Rossi C; Parente P; Ascani S
    Pathol Res Pract; 2020 Jun; 216(6):152973. PubMed ID: 32370987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
    Migkou M; Gavriatopoulou M; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2018 Jun; 11(6):463-469. PubMed ID: 29788798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Newest Advances in Diagnosis and Treatment of Plasmablastic Lymphoma --Review].
    Peng HL; Yang HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1594-1598. PubMed ID: 37846723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral plasmablastic lymphoma: A case report.
    Zizzo M; Zanelli M; Martiniani R; Sanguedolce F; De Marco L; Martino G; Parente P; Annessi V; Manzini L; Ascani S
    Medicine (Baltimore); 2020 Sep; 99(39):e22335. PubMed ID: 32991445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS.
    Basavaraj A; Kadam M; Kadam DB
    J Assoc Physicians India; 2016 May; 64(5):71-72. PubMed ID: 27735156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
    Lipstein M; O'Connor O; Montanari F; Paoluzzi L; Bongero D; Bhagat G
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):E43-6. PubMed ID: 21856550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
    Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
    Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.